Botulinum toxin type A + Placebo

Phase 2/3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Plantar Fasciitis

Conditions

Chronic Plantar Fasciitis

Trial Timeline

Jul 1, 2005 → Apr 1, 2009

NCT ID

NCT00447876

About Botulinum toxin type A + Placebo

Botulinum toxin type A + Placebo is a phase 2/3 stage product being developed by Ipsen for Chronic Plantar Fasciitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00447876. Target conditions include Chronic Plantar Fasciitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03569098	Phase 2	Completed	Jun 19, 2018	May 22, 2020	Hallux Abducto Valgus
NCT03598777	Phase 2	Terminated	Jun 11, 2018	Jan 21, 2021	Vulvodynia
NCT02493946	Phase 3	Completed	Apr 1, 2015	Dec 1, 2016	Glabellar Lines
NCT02353871	Phase 3	Completed	Jan 1, 2015	Aug 1, 2015	Moderate to Severe Glabellar Lines
NCT02321436	Approved	Completed	Dec 1, 2014	Mar 1, 2016	Stroke
NCT01753310	Phase 3	Completed	Jan 1, 2013	Jan 1, 2015	Cervical Dystonia
NCT01249417	Phase 3	Completed	Jul 1, 2011	Jun 1, 2014	Cerebral Palsy
NCT01357980	Phase 2	Completed	May 1, 2011	Mar 1, 2013	Detrusor Muscle Hyperactivity
NCT01249404	Phase 3	Completed	Mar 1, 2011	May 1, 2014	Leg Spasticity
NCT00578097	Phase 2	Terminated	Feb 1, 2008	Dec 1, 2009	Overactive Bladder
NCT00257660	Phase 3	Completed	Oct 10, 2005	Sep 1, 2006	Cervical Dystonia
NCT00447876	Phase 2/3	Completed	Jul 1, 2005	Apr 1, 2009	Chronic Plantar Fasciitis
NCT00216411	Approved	Completed	Nov 1, 2004	Jul 20, 2006	Cerebrovascular Accident
NCT00234546	Approved	Completed	Feb 1, 2003	Oct 1, 2007	Muscle Spasticity

Competing Products

20 competing products in Chronic Plantar Fasciitis

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved

lanreotide acetateApproved

Tigan® + PlaceboApproved

Diosmectite (Smecta®)Approved

lanreotide (Autogel formulation)Approved